Immunome shares surge 10.78% intraday as Merck partners with Infinimmune and varegacestat Phase III trial shows positive top-line results.

Immunome surged 10.78% intraday, driven by three key factors: 1) media reports of Merck's $838 million collaboration with antibody discovery company Infinimmune, drawing attention to Immunome in the same space; 2) positive topline results from the Phase III RINGSIDE trial of its core product varegacestat, with an NDA planned for Q2 2026; and 3) CEO purchasing 25,450 shares at an average price of $20.16, signaling confidence in the company.